Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Q3/10 Results, NeoStem (AMEX: NBS)

NBS reported a net loss of $7.14M or ($0.13) per share.

Revenues were $16.475M comprised of $16.38M of pharmaceutical product sales, $30K from stem cell therapies in China and $61.1K related to stem cell collections, license fees, royalties and other revenue in the US. Gross margin totaled $5,2M of which 99% is attributable to the sale of pharmaceutical products and the balance is attributable to stem cell collection and therapy operations. Costs of revenues were $11.32M. R&D expenses totaled $1.68M. SG&A expense was $9.6M. Net loss from operations was $5.9M. A factor of net income attributable to non-controlling interest ($1.146M) added to net loss based on weighted common shares outstanding of 56.77M.

  • At 9/30/10, NBS had a cash and equivalents of $4M, working capital of $7.7M and shareholders’ equity of $45.6M